Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DR-2001a
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Vaginal
01
Overview
DR-2001a is an investigational drug evaluated for the management of endometriosis-related pelvic pain. It was administered vaginally in clinical studies, suggesting a local delivery approach targeting endometrial tissue. The precise mechanism of action, molecular target, and chemical class are not specified in available public sources. The drug appears to be distinct from other similarly named compounds and is not a known generic or biosimilar of any approved medication[1][4].
- Other names
- DR-2001aDR2001aDR 2001a
Beyond the preview
Go deeper on DR-2001a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DR-2001a.